Skip to main content

Table 1 Overview of basic characteristics of heart failure and cardiovascular outcome trials published in 2021

From: Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes

Study name Study status Drug Drug class Intervention Primary outcome n Median follow up Start and end date ID
EMPEROR-preserved [37] Completed Empagliflozin SGLT2 inhibitor Empagliflozin 10 mg once daily vs. placebo Composite of CV death or HHF 5988 2.2 03.2017–04.2021 NCT03057951
Completed Finerenone Mineralocorticoid receptor antagonist Finerenone 10 mg or 20 mg once daily vs. placebo Composite of death from CV causes, nonfatal MI, nonfatal stroke, or HHF 8246 3.4 09.2015–02.2021 NCT02545049
Terminated Efpeglenatide GLP-1 receptor agonist Efpeglenatide 4 mg or 6 mg subcutaneous once a week vs. placebo Composite of nonfatal MI, nonfatal stroke, or death from CV or undetermined causes 4077 1.8 04.2018–12.2020 NCT03496298
  1. HHF hospitalization for heart failure